Boxer Capital’s Apogee Therapeutics APGE Stock Holding History

Boxer Capital’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-179,000	Closed	-$10.5M	–	3
2024 Q3	$10.5M	Buy	+179,000	New	+$8.58M	0.52%	44

Other funds holding APGE

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Boxer Capital's APGE Position: Q4 2024 in Review

Boxer Capital sold out of Apogee Therapeutics (APGE) in Q4 2024, closing a stake of 179,000 shares — an estimated $10.5M sold.

Boxer Capital first reported a position in APGE in Q3 2024 and held it in 1 quarter. The position peaked at $10.5M in Q3 2024. 157 funds tracked by Wall St. Rank hold APGE as of Q4 2024.

Boxer Capital reported no remaining Apogee Therapeutics position as of Q4 2024 after selling out during the quarter.
Boxer Capital sold 179,000 Apogee Therapeutics shares in Q4 2024, an estimated $10.5M.
Boxer Capital first reported a position in Apogee Therapeutics in Q3 2024 and held it in 1 quarter.
Boxer Capital's Apogee Therapeutics position peaked at $10.5M in Q3 2024.
157 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.